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(15%) had abdominal bloating in Gp-L,
while 3 (5%) patients experienced abdom-
inal pain and nausea in rifaximin, but no
patient was withdrawn from the trial due to
these adverse effects. Baseline MELD score,
Child-Turcotte-Pugh score, bilirubin, arter-
ial ammonia, heart rate, mean arterial pres-
sure and total leucocyte count significantly
correlated with development of HE. On
multivariate analysis, only baseline arterial
ammonia and blood transfusion require-
ment during hospital stay were the predic-
tors of development of HE (table 3).
The results of two recently published
meta-analyses which compared the efficacy
of oral non-absorbable disaccharides
versus rifaximin in the management HE
showed that both lactulose and rifaximin
are equally effective and rifaximin is better
tolerated.6 7 In our study, rifaximin was
not superior to lactulose for prophylaxis
of HE in patients of cirrhosis with AVB
and well tolerated. It will be worthwhile to
give rifaximin or lactulose as a standard
treatment in the management of AVB in
patients with cirrhosis to prevent HE con-
sidering the prognosis, burden and asso-
ciated cost in the management of HE.
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Limited resection of pancreatic
cancer in high-risk patients
can result in a second primary
Dear Editor,
We read with interest the paper by Canto
and coworkers recently published in Gut
that provided guidelines for the manage-
ment of individuals with a high risk
for pancreatic ductal adenocarcinoma
(PDAC).1 Although indications for surgery
Table 1 Characteristics of bleed at the time of enrolment in two groups
Parameters Lactulose group (n=60) Rifaximin group (n=60) p Value
Hb (g/L) 77±15 78±13 0.27
Heart rate (bpm) 108.2±9.7 106.9±12.1 0.09
Mean arterial pressure (mm Hg) 79.3±6.1 82.1±6.9 0.34
Blood units transfused 1.9±1.0 1.7±1.1 0.46
Time to endoscopy (h) 6.3±1.6 6.1±1.7 0.64
Source of bleeding (%)
Oesophageal varices 90 92 0.72
Gastric varices 7 5
Oesophageal+gastric varices 3 3
Active bleeding at endoscopy n (%) 17 (28) 14 (23) 0.77
Vasoactive therapy (%) 100 100 1.0
Banding or cyanoacrylate injection (%)
Banding 93 95 0.72
Cyanoacrylate injection 10 8
Course of bleeding
Failure to control bleeding 7 (11.6%) 6 (10%) 0.38
Table 2 Primary and secondary outcomes of the study in two groups
Outcome Lactulose group (n=60) Rifaximin group (n=60) p Value
HE (n) 10 9 1.0
Death (n) 8 9 1.0
Hospital stay in days
Patients with HE 12.4±3.5 10.6±3.1 0.35
Patients without HE 6.9±1.9 6.3±1.6 0.18
p Value=0.001 (significant difference for hospital stay between patients who developed HE vs those who did not
develop HE).
HE, hepatic encephalopathy.
Table 3 Multivariate analysis for patients
who developed hepatic encephalopathy
Parameters p Value CI
Arterial ammonia 0.03 0.71 to 0.94
CTP score 0.72 0.26 to 2.85
MELD score 0.68 0.24 to 2.14
Mean arterial pressure 0.09 0.88 to 1.35
Heart rate 0.07 0.96 to 1.26
Blood transfusion
requirement
0.04 0.09 to 0.96
Aetiology 0.36 0.08 to 1.94
Bilirubin 0.54 0.52 to 1.56
Total leucocyte count 0.71 0.94 to 1.10
CTP score, Child-Turcotte-Pugh score; MELD, model
for end stage liver disease.
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are discussed, no recommendations are
given regarding the extent of surgery, that
is, partial pancreatectomy (PP) or total pan-
createctomy (TP), in cases with a small
screen-detected PDAC. This is an important
issue because it seems very likely that a her-
editary background increases the risk for a
second primary cancer of the pancreas.
Here, we describe two high-risk individuals
who developed a second primary tumour
after a PP of an early-stage cancer.
Patient 1 is a 62-year-old woman with
the common Dutch ‘p16-Leiden’ founder
mutation in the CDKN2A gene and a
medical history of melanoma at age 56.
This patient was enrolled in the surveillance
programme in Leiden in 2008. The first
MRI showed a lesion in the head–corpus
region of the pancreas, suspicious for an
adenocarcinoma. The lesion was confirmed
by CT scanning, with no signs of distant
metastases. A partial duodenopancreatect-
omy was performed. Histopathological
examination showed a well-differentiated
adenocarcinoma of 5 mm, surrounded by
PanIN1 lesions and an intraductal papillary
mucinous neoplasm lesion. The resection
margins were free of tumour and seven
lymph nodes were unaffected (T1N0M0).
A KRAS hotspot mutation in codon 12 was
detected in the tumour (c.35G>T). This
patient continued pancreatic surveillance.
After 54 months, a solitary lesion of 7 mm
was found in the corpus–tail region with
endoscopic ultrasound (EUS). Cytological
examination of an EUS-guided fine-needle
aspirate showed atypical cells compatible
with adenocarcinoma. Of note, no KRAS
mutation was detected in these cells. CT
scanning confirmed the presence of the
lesion without evidence for distant
metastases. A completion pancreatectomy
with splenectomy was performed and histo-
pathological examination showed one small
duct suspicious for adenocarcinoma sur-
rounded by multifocal PanIN1-3 lesions.
The resection margins of the specimen
were free of tumour and 13 lymph nodes
were unaffected (T1N0M0). Fifteen
months after pancreatectomy, the patient is
alive with no evidence of disease.
Patient 2 is a 46-year-old woman with a
germline mutation in the BRCA2 gene and
three relatives with PDAC. In 1984, she
developed a painless icterus; CT scanning
and endoscopic retrogade cholangio-
pancreatography revealed a tumour in the
pancreatic head. A partial duodenopancrea-
tectomy was performed. Histopathological
examination showed a moderately differen-
tiated PDAC of 22 mm. The resection
margins were free of tumour and none
of 14 lymph nodes were affected.
(T2N0M0). In 1987, 33 months later, the
tumour marker carbohydrate antigen 19.9
increased to 190 U/mL (normal <39 U/mL)
and CT scanning revealed a tumour in the
tail of the pancreas. A resection of the
remnant pancreas was performed and histo-
pathological examination showed a poorly
differentiated adenocarcinoma of 20 mm.
The resection margins and eight lymph
nodes were free of tumour (T2N0M0). At
the last follow-up 28 years after completion
pancreatectomy the patient is alive with no
evidence of PDAC.
What are the implications of our find-
ings? Should we offer TP to all patients
with a genetic predisposition and an
early-stage cancer? A well-known disad-
vantage of TP is the development of
‘brittle’ diabetes which is associated with
substantial morbidity. However, recent
studies all concluded that TP is safe, with
acceptable mortality and morbidity.2 3
Studies that compared the perioperative
mortality and morbidity of TP with PP
produced more conflicting results4–10 (see
table 1). Two recent reports demonstrated
that the quality of life following TP is
acceptable and similar to that reported
for PP.3 5
In light of these recent studies, the best
approach is to discuss the various advan-
tages and disadvantages of TP with high-
risk patients with early-stage PDAC and
come to a decision together.
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Reference Cohort Mortality (%)
Sign.
(p value) Morbidity (%)
Sign.
(p value)
Schmidt et al4 TP n=33 6 n.s. 36 n.s.
PD n=28 7 54
Muller et al5 TP n=87 6 n.s. 31 n.s.
PD n=87 3 23
McPhee et al6 TP n=1399 8.3 0.0002 n/a n/a
PD n=27 289 6.6 n/a
Reddy et al7 Period 1970–2007
TP n=100 8 69




PD 1.2 0.17 No significant change
Nathan et al8 TP n=376 8.6 n/a
PP n=3645 6.3 0.09 n/a n/a
Simons et al9 TP n=5966 OR 2.90 OR 1.29
PD n=56 207 Ref. <0.0001 Ref. 0.0025
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Immunogenicity to infliximab
is associated with HLA-DRB1
Dear Editor,
We read with great interest the manuscript
by Ungar and colleagues describing the
temporal evolution of antibodies to inflixi-
mab (ATI) in patients with IBD treated with
infliximab (IFX).1 By prospectively follow-
ing 125 patients with IBD, they showed
that ATI formation is a dynamic process.
Clinically relevant ATI were typically
formed within the first 12 months but tran-
sient ATI, which are of little clinical signifi-
cance, can be formed at any time during
treatment. They furthermore demonstrated
that the evolution of ATI correlates with
clinical loss of response and that concomi-
tant immunomodulator use prolonged
ATI-free survival, which is in line with pre-
vious reports. Nevertheless, patient-related
factors possibly influencing ATI formation
weren’t considered and haven’t been
studied extensively. We hypothesised that
ATI formation may be triggered by
HLA-DRB1 alleles, as was shown for
immunogenicity to interferon-β therapy in
multiple sclerosis.2 We retrospectively ana-
lysed 192 patients with IBD: 76 patients
developed ATI during IFX maintenance
treatment (=ATI+) (44 Crohn’s disease
(CD), 32 UC) and these were matched with
116 patients (64 CD, 52 UC) who never
developed ATI (=ATI−). All patients were
antitumour necrosis factor naïve before IFX
initiation, and the ATI group required at
least 2 years of IFX maintenance therapy.
We measured drug concentrations and ATI
at trough (in-house-developed ELISA, KU
Leuven) and HLA-DRB1 alleles were
typed using sequence-specific primer PCR
(Prometheus Laboratories). Similar to the
findings of Ungar et al, the majority of ATI
(73.6%) developed during the first year of
treatment. At IFX start, the use of a loading
dose at weeks 0–2–6 and a higher albumin
level were protective for ATI formation
(p<0.05). Carriage of the HLA-DRB1*03
allele was more prevalent in ATI+ (13%)
than in ATI− patients (4%; p=0.002, OR
(95% CI) 3.6 (1.5 to 8.6)) and the
HLA-DRB1*13 was less prevalent in ATI+
(8%) than in ATI− patients (16%; p=0.02,
OR 0.44 (0.22 to 0.91)) (figure 1). After
correction for multiple testing, DRB1*03
remained significantly associated with ATI
formation (pcorr=0.02). Multiple stepwise
logistic regression withheld the presence of
DRB1*03, absence of a loading dose and
IFX monotherapy as independent predic-
tors of ATI formation with OR 6.7 (2.3 to
19.5, p=0.0005), 2.9 (1.4 to 6.3,
p=0.004) and 2.0 (0.98 to 4.1, p=0.056),
respectively.
HLA-DR is the protein of which the β1
subunit is encoded by HLA-DRB1.
Different HLA-DRB1 alleles encode for
different amino acid sequences in this
β1-chain. We therefore also examined
single amino acids in the DR β1-chain.
These amino acid sequences were available
through the IIBDGC HLA fine-mapping
project3 in 71% (136/192) of our patients.
The presence of arginine at position 74
and absence of glutamate at position 71
were associated with ATI formation (OR
Figure 1 Log OR plot for ATI (antibodies to infliximab) formation according to the different
HLA-DRB1 alleles (showing only alleles with an overall frequency >5%).
Figure 2 Three-dimensional ribbon model for HLA-DR protein. This structure, with a direct view
of the peptide-binding groove, is based on Protein Data Bank entry 3pdo. The amino acids
identified by the association analysis are highlighted. This figure was prepared using UCSF
Chimera (http://www.cgl.ucsf.edu/chimera).
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